臨床神経学

<シンポジウム(3)―3―1>中枢神経を侵す難治性炎症性疾患の治療法の選択と最適化:Q&A

慢性進行型多発性硬化症

新野 正明

北海道医療センター臨床研究部〔〒063―0005 札幌市西区山の手5条7丁目1―1〕

Progressive type multiple sclerosis (MS) is usually divided into primary progressive MS (PPMS) and secondary progressive MS (SPMS), and the two types might be different pathologic entities. Some disease modifying therapies may be effective for progressive type MS. However, no class I evidence is currently available on initiating treatment for patients with either of the progressive types, and current treatment options for progressive type MS are limited. Moreover, there have been few curative treatments for various disabilities the disease cause. In the current situation, health-related quality of life (HRQOL) is an important issue for patients, and physicians should pay attention to improving this aspect of their life. In the near future, drugs for axonal regeneration and remyelination may become treatment options for patients with progressive type MS.
Full Text of this Article in Japanese PDF (160K)

(臨床神経, 52:1229−1230, 2012)
key words:多発性硬化症,進行型,治療,生活の質

(受付日:2012年5月25日)